US EditionPublished • loading... • Updated
Bayer Collaborates with Cradle to Scale Generative AI in Antibody Discovery
Summary by healtheconomics.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Bayer Collaborates with Cradle to Scale Generative AI in Antibody Discovery
Bayer has entered a three-year strategic collaboration with Cradle to integrate its generative AI software into Bayer’s biologics R&D workflow. The partnership aims to enhance the discovery and optimization of therapeutic antibodies by utilizing “lab-in-the-loop” AI to design higher-quality molecules. By streamlining the design-test-learn cycle, the collaboration seeks to improve the potency, safety, and manufacturability of drug candidates whil…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
